Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$90.0M
12M shares
52-week range
$2.20 – $9.33
69% from low
Sector
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Exchange
XASE
CS
Borrow rate
0.43%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.9M | $2.7M | $2.7M | $2.5M | $2.7M | $3.6M |
| Cost of revenue | $481.1K | $467.7K | $297.1K | $303.3K | $362.0K | $562.9K |
| Gross profit | $1.4M | $2.3M | $2.4M | $2.2M | $2.3M | $3.0M |
| Gross margin | 75.1% | 82.8% | 88.9% | 87.7% | 86.5% | 84.2% |
| R&D | $166.8K | $203.4K | $225.6K | $169.3K | $206.1K | $493.6K |
| Operating income | −$4.1M | −$3.0M | −$3.4M | −$6.7M | −$7.2M | −$7.8M |
| EBITDA | −$3.6M | −$3.0M | −$4.3M | −$9.2M | −$7.9M | −$7.7M |
| Net income | −$3.7M | −$3.0M | −$4.8M | −$14.6M | −$8.2M | −$7.8M |
| Net margin | -193.0% | -111.3% | -178.0% | -594.6% | -306.8% | -218.5% |
| EPS (diluted) | -0.80 | -0.62 | -0.78 | -2.32 | -1.22 | -0.95 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $10M | $-0.68 | $-0.84–$-0.52 | 2 |
| 2027 | $21M | $-0.06 | $-0.06–$-0.06 | 1 |
| 2028 | $33M | $0.39 | $0.38–$0.40 | 1 |
Forward consensus · source: Financial Modeling Prep
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
www.neuraxis.comNo one on the platform currently holds NRXS.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 76,954 | $569.5K |
No one on the platform has traded NRXS yet.
| $20M |
| — |
| NERVMinerva Neurosciences, Inc. | $5.43 | +24.26% | $38M | — |
| NRSNNeuroSense Therapeutics Ltd. | $0.71 | -6.27% | $18M | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 16.8× sales vs its 7.6× historical median P/S.
Fair value ≈ $3.24 · price $7.14 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$NRXS Commerical coverage win will happen likely August-October. I read more stuff today. So my earlier post June-July was misleading. But you never know. Q2 earnings report next catalyst in August.
View on StockTwits ↗$NRXS MVC will also post public Q2 recap on 1st July. NRXS his second biggest position (orange) after NBIS.. call it top high conviction stock.. NBIS gang will roll the profits into NRXS next.. MVC and his followers start to pump stock to $15 after coverage win !! lets see
View on StockTwits ↗$NRXS Major commercial coverage win very likely in July or August.
View on StockTwits ↗$NRXS MicroCapClub and Mr. Cunha stopped posting stuff -> share price taking a deep breath. But now, share price under $7 and during next month a big commercial insurance coverage win is quite possible!! I think Q2 numbers are not epic but people underestimate growth potential in the next 1-2 years! Stock will double in a year.
View on StockTwits ↗$NRXS If stock drops to 5s, it wont be there long time bc that triggers multiple substack articles and twitter posts.
View on StockTwits ↗$NRXS Does someone know when they announce the coverage? According history H2 June- July is very active time to announce new policy changes. Coverage can kick in right away or e.g start of August/September.
View on StockTwits ↗$NRXS Hey everyone, just realized that there is a community here for NeurAxis. Done A TON of research on this company, can confidently say i’m a VERY bullish on this company, absolutely 0 reason to NOT buy this stock, going to easily 2x by EOY!
View on StockTwits ↗$NRXS Sold all low 8s and 7.5s. I realized stock performance is all about Cunha's twitter posts and substrack. He became quiet so i sold. I bought first batch back at $7.1 .. no catalyst before potential coverage win late June/July. 1Y PT $15. By the end of year $10. Max pain is $6.4. Triggers multiple twitter posts and new deep dive. At $5.9 Microcapclub step in with new Ceo interview.
View on StockTwits ↗$NRXS https://microcapopportunities.substack.com/p/neuraxis-va-ramp
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.